Myocarditis after vaccination, firm data

John, please could you review this article from Israel national News, it says the risk of myocarditis following mRNA COVID vaccination is around 133 times greater than the background risk in the population, is this true? If it is true, why is this not all over MSM?

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 (25 January)

JAMA. 2022;327(4):331-340. doi:10.1001/jama.2021.24110

Importance

Vaccination against COVID-19 provides clear public health benefits,

but vaccination also carries potential risks.

The risks and outcomes of myocarditis after COVID-19 vaccination are unclear.

To describe reports of myocarditis and the reporting rates after mRNA-based COVID-19 vaccination in the US.

Descriptive study

Reports of myocarditis to the Vaccine Adverse Event Reporting System (VAERS)

After mRNA-based COVID-19 vaccine administration

Between December 2020 and August 2021 in

n = 192,405,448 older than 12 years of age in the US

During the analytic period

BNT162b2 vaccine, 12 years and older

mRNA-1273 vaccine, 18 years and over

Exposures

Vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)

Main Outcomes and Measures

Expected rates of myocarditis by age and sex were calculated using 2017-2019 claims data.

For persons younger than 30 years of age, medical record reviews and clinician interviews were conducted to describe clinical presentation, diagnostic test results, treatment, and early outcomes.

Results

Among 192,405,448 persons

Receiving a total of 354,100, 845 mRNA vaccines

1,991 reports of myocarditis to VAERS

1,626 met the case definition of myocarditis

Of those with myocarditis

Median age, 21 years (IQR, 16-31 years)

Median time to symptom onset, 2 days (IQR, 1-3 days)

Males

Comprised 82% of myocarditis cases

Reporting rates for cases of myocarditis

Within 7 days after COVID-19 vaccination,

exceeded the expected rates of myocarditis across multiple age and sex strata

Rates of myocarditis were highest after the second vaccination dose

Adolescent males aged 12 to 15 years

70.7 per million doses of the BNT162b2 vaccine

(One case per 14,144 vaccinations)

Males aged 16 to 17 years

105.9 per million doses of the BNT162b2 vaccine

(One case per 9,442 vaccinations)

Males aged 18 to 24 years

52.4 per million doses of the BNT162b2 vaccine

(One case per 19,083 vaccinations)

56.3 per million doses of the mRNA-1273 vaccine

(One case per 17,761 vaccinations)

Myocarditis in the under 30s

826 cases of myocarditis, who had detailed clinical information available

Of these 826 cases of myocarditis

792 of 809 (98%) had elevated troponin levels

569 of 794 (72%) had abnormal electrocardiogram results

223 of 312 (72%) had abnormal cardiac magnetic resonance imaging results

Hospital data

784 of 813 (96%) were hospitalized

577 of 661 (87%) had resolution of presenting symptoms by hospital discharge

Most common treatment

Nonsteroidal anti-inflammatory drugs 589 of 676 (87%).

7.26 + 105.86 = 113.12

Expected, 1.34

113.12

= 84.4

1.34

Supplement

CDC’s case definition of probable myocarditis